Literature DB >> 16829852

Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.

Alexander Roesch1, Sina Wittschier, Bernd Becker, Michael Landthaler, Thomas Vogt.   

Abstract

The deep penetrating nevus is a rare variant of benign melanocytic nevus with histologic features mimicking vertical growth phase, nodular malignant melanoma. In this study, we expand on the search for new complementary discriminating markers by analyzing a selection of both cell cycle-related factors, such as retinoblastoma protein and phospho-retinoblastoma protein Ser795 as indicators for retinoblastoma protein activation/inactivation status, and invasion-related factors, such as matrix metalloproteinase-1, matrix metalloproteinase-2, membrane-type matrix metalloproteinase-1 and integrin beta3. MIB-1/Ki-67 was analyzed as an example for a common proliferation marker. Dipeptidyl peptidase IV/CD26 was analyzed as a marker affecting both proliferation and invasion of malignant melanocytic tumors. Semiquantitative assessment of both immunolocalization and immunoreactivity of retinoblastoma protein and phospho-retinoblastoma protein Ser795, MIB-1/Ki-67, matrix metalloproteinase-1, matrix metalloproteinase-2, membrane-type matrix metalloproteinase-1 and integrin beta3 revealed no consistent differences between deep penetrating nevi (n=14) and matched cases of nodular malignant melanomas (n=10). Matrix metalloproteinase-1 and matrix metalloproteinase-2 immunostaining of some deep penetrating nevi even exceeded that of nodular malignant melanomas. Membrane-type matrix metalloproteinase-1 expression scores of nodular malignant melanomas were higher than those of deep penetrating nevi, which was, however, not significantly discriminative. In contrast, immunostaining of dipeptidyl peptidase IV was significantly discriminative due to a consistent lack of dipeptidyl peptidase IV-expression in nodular malignant melanomas. These results add evidence that among the selected markers supposed to be relevant for melanoma progression the presence of dipeptidyl peptidase IV can be used to support diagnosis of deep penetrating nevi in doubtful cases. As loss of dipeptidyl peptidase IV may also be causally linked to the transition of invasive to metastatic phenotypes, the molecular mechanisms downstream of dipeptidyl peptidase IV deserve to be studied in more detail in future investigations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829852     DOI: 10.1038/modpathol.3800663

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients.

Authors:  Kellie J Archer; Valeria R Mas; Krystle David; Daniel G Maluf; Karen Bornstein; Robert A Fisher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

Review 2.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

3.  Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.

Authors:  H J Choi; J Y Kim; S-C Lim; G Kim; H J Yun; H S Choi
Journal:  Br J Pharmacol       Date:  2015-10-16       Impact factor: 8.739

4.  The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes.

Authors:  Wei Zhao; Joseph Mazar; Bongyong Lee; Junko Sawada; Jian-Liang Li; John Shelley; Subramaniam Govindarajan; Dwight Towler; John S Mattick; Masanobu Komatsu; Marcel E Dinger; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2016-01-29       Impact factor: 8.551

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

6.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

7.  Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.

Authors:  Byungwoo Ryu; Dave S Kim; Amena M Deluca; Rhoda M Alani
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

Review 8.  Conventional and Atypical Deep Penetrating Nevus, Deep Penetrating Nevus-like Melanoma, and Related Variants.

Authors:  Pavandeep Gill; Phyu P Aung
Journal:  Biology (Basel)       Date:  2022-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.